Nutriband Inc. NTRB Archives - Page 4 of 6

TuesdayMay 27, 2025 9:10 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast

Nutriband (NASDAQ: NTRB) is featured in the latest episode of The BioMedWire Podcast, part of IBN’s expanding podcast network focused on biotech and pharmaceutical innovation. In a conversation with host Carmel Fisher, Nutriband Co-Founder and CEO Gareth Sheridan outlined the company’s focus on transdermal drug delivery systems, particularly in the underserved area of pain management. Sheridan emphasized the impact of the opioid crisis on patient access to effective medications, noting that the stigma and liability concerns surrounding opioids have left many pain patients without adequate care. He introduced AVERSA(TM), Nutriband’s internally developed platform designed to deter abuse of opioid patches by…

ThursdayMay 22, 2025 10:30 am

Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization

AVERSA Fentanyl has potential to become the world’s first opioid pain patch with abuse deterrent properties, CEO states in report Nutriband and Kindeva Drug Delivery have formalized a strong product-development partnership and long-term commitment Other key steps outlined as company works to develop, scale-up manufacturing process to bring Aversa technology closer toward commercialization In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 (https://ibn.fm/9K5zT). At the center of the company’s positive outlook for future is noteworthy progress made toward the commercialization of its proprietary Aversa…

ThursdayMay 15, 2025 2:40 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential to be the world’s first and only abuse deterrent patch platform for managing chronic pain. The company also deepened its collaboration with Kindeva Drug Delivery through an amended agreement focused on the development of Aversa(TM) Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl…

TuesdayMay 13, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch

The opioid epidemic has prompted a re-evaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention Nutriband's AVERSA(TM) Fentanyl represents a significant advancement in this domain The company’s strategic development of AVERSA Fentanyl follows a structured pharmaceutical lifecycle As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband's development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach…

FridayMay 09, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

Nutriband’s AVERSA(TM) technology is advancing toward commercialization as the first abuse-deterrent transdermal fentanyl patch Recent FDA regulatory changes underscore the urgent need for safer opioid delivery methods and responsible prescribing Strategic milestones with partner Kindeva and a strengthened global IP portfolio position Nutriband for long-term growth A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid…

WednesdayApr 30, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Leadership Team: Driving Innovation and Shaping the Future of Global Healthcare

Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year Awards The CEO’s international perspective and expertise were further validated when he was featured in a recent BBC News article Chairman Serguei Melnik also participated in a market interview where he spoke about Nutriband’s mission, achievements and plans for the future Nutriband (NASDAQ: NTRB) is earning widespread recognition for the board’s leadership, expertise and innovation across a variety of platforms. Sheridan has recently been acknowledged in several high-profile ways that affirm his growing influence as a respected professional in the healthcare and business sectors. From…

TuesdayApr 22, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery

Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform AVERSA(TM) Fentanyl targets $80M–$200M U.S. sales opportunity as first abuse-deterrent opioid patch Strategic sports partnership with Charlotte FC boosts brand visibility and community presence Strengthening IP for Long-Term Market Protection Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark Office (“USPTO”) for “Nutriband(TM),” covering pharmaceutical and product R&D. This comes in addition to a newly granted patent in Macao for its proprietary AVERSA(TM) transdermal system, bringing the total number…

TuesdayApr 15, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients. AVERSA technology can be incorporated into any transdermal patch. The company has a broad and expanding intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. Nutriband closed an $8.4 million financing round in April 2024 to support commercial development of AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch. In February 2025, the company formalized a long-term exclusive partnership with Kindeva Drug Delivery to support…

MondayApr 14, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of patients Nutriband recently announced two significant partnerships poised to expand its manufacturing capabilities and market reach These partnerships, along with the company’s already existing alliances, align with Nutriband's core mission of developing transdermal pharmaceutical products Strategic alliances are vital to success in the pharmaceutical sector, where innovation, regulatory navigation and market access are complex and resource-intensive. Collaborations between biotech firms, research institutions and major pharmaceutical companies accelerate drug development, reduce costs and enhance the likelihood of regulatory approval. Nutriband (NASDAQ: NTRB), a company focused on…

FridayApr 11, 2025 8:50 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures Patent in Macao for AVERSA Abuse-Deterrent Technology

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has been granted a patent in Macao for its AVERSA™ abuse-deterrent transdermal technology. The patent, titled “Abuse and Misuse Deterrent Transdermal Systems,” was granted on Feb. 11 and recorded in Macao’s Official Bulletin on Mar. 5. This adds to Nutriband’s global IP portfolio, with coverage now spanning 46 countries and both SARs of China. AVERSA is designed to reduce abuse, diversion and accidental exposure of transdermal drugs like opioids. Nutriband is advancing development of AVERSA Fentanyl with partner Kindeva Drug Delivery, aiming to commercialize the world’s first abuse-deterrent fentanyl patch…

Site Search

Company Search

Tag: Nutriband Inc. NTRB